BTC Health Limited (ASX:BTC), a Pooled Development Fund focused on medical products in Australia and New Zealand, has disclosed its Net Tangible Asset backing for October 2026, reporting a total board valuation of $10,443,983, equivalent to 2.91 cents per BTC share.
Key Points
- Total board valuation of $10,443,983, equivalent to 2.91 cents per BTC share
- Total unlisted securities valued at $7,462,279, representing 2.09 cents per share
- Net cash of $1,122,486, equivalent to 0.30 cents per share
- Net loans to subsidiaries of $1,900,000, equivalent to 0.53 cents per share
Unlisted Securities Valuation Breakdown
According to the filing, BTC Health's unlisted securities comprise three subsidiary holdings. BTC Pharma Pty Ltd was valued at $637,607, equating to 0.18 cents per share. BTC Cardio Pty Ltd was valued at $3,899,767, equating to 1.09 cents per share. BTC Speciality Health Pty Ltd was valued at $2,924,905, equating to 0.82 cents per share. The combined total for unlisted securities was $7,462,279, representing 2.09 cents per BTC share. The filing states that the board valuation is based upon the investment policy of the Board and is broadly in line with industry standard practices.
Net Cash, Loans and Other Assets
The October 2026 NTA disclosure also sets out the company's remaining balance sheet items. Net loans to subsidiaries were recorded at $1,900,000, equating to 0.53 cents per share. Net cash stood at $1,122,486, equivalent to 0.30 cents per share. Net other assets were recorded at negative $40,782, equating to negative 0.01 cents per share. The tax provision was recorded at nil. These items, combined with the unlisted securities total, produced the aggregate board valuation of $10,443,983, or 2.91 cents per BTC share.
Authorisation and Company Description
The filing states the disclosure was authorised for release by Dr. Richard Treagus, Executive Chairman of BTC Health Limited. According to the filing, BTC Health Ltd is a Pooled Development Fund that makes active investments in businesses that acquire, develop and distribute innovative medical products in Australia and New Zealand. The company is described as building a group of high-growth businesses focused on providing access to specialised therapeutics and medical devices from around the world. The filing also notes that the timing of regulatory approval in India, and the level of any sales in India, are uncertain.




Please wait processing your request...